Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBSC-M87o gene-modified CD34+ hematopoietic stem cells
- Development stage
- Unknown
- Lead developer
- University Medical Center Hamburg-Eppendorf
- Modality
- Gene Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
PBSC-M87o gene-modified CD34+ hematopoietic stem cells is an investigational autologous or allogeneic gene-modified cell therapy developed by the University Medical Center Hamburg-Eppendorf. The therapy involves the ex vivo transduction of peripheral blood-derived CD34+ hematopoietic stem cells (HSCs) with the M87o retroviral vector. This vector expresses a membrane-anchored C-peptide derived from the HIV-1 gp41 region, which acts as a fusion inhibitor to prevent HIV-1 entry into the cell. The primary objective is to reconstitute an HIV-resistant immune system in HIV-positive patients who are undergoing high-dose chemotherapy and hematopoietic stem cell transplantation for hematologic malignancies, such as lymphoma. By providing a population of cells resistant to productive HIV-1 infection, the therapy aims to control viral replication while simultaneously treating the underlying cancer.
- Other names
- M87o-transduced CD34+ cellsgene-modified CD34+ hematopoietic stem cells
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on PBSC-M87o gene-modified CD34+ hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBSC-M87o gene-modified CD34+ hematopoietic stem cells.